Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: A European multicenter study

Leukemia

Volumn 23, Issue 8, 2009, Pages 1472-1479

  Willasch, A M ^a   Gruhn, B ^b   Coliva, T ^c   Kalinova, M ^d   Schneider, G ^a   Kreyenberg, H ^a   Steinbach, D ^e   Weber, G ^a   Hollink, I H I M ^f   Zwaan, C M ^f   Biondi, A ^c   van der Velden, V H J ^g   Reinhardt, D ^h   Cazzaniga, G ^c   Bader, P ^a   Trka, J ^d  

^a GOETHE UNIVERSITY   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c Clin Pediat Univ Milano Bicocca   (Italy)

^d CHARLES UNIVERSITY   (Czech Republic)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; MESSENGER RNA; WT1 PROTEIN;

ACCURACY; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE;

EID: 68749092656     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.51     Document Type: Article

References (35)

1. Cilloni D, Saglio G. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 2004; 112: 79-84.
2. Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, Perot C et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 2006; 24: 1507-1515.
3. Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T et al Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005; 19: 1416-1423.
4. Barragan E, Cervera J, Bolufer P, Ballester S, Martin G, Fernandez P et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004; 89: 926-933.
5. Steinbach D, Schramm A, Eggert A, Onda M, Dawczynski K, Rump A et al Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res 2006; 12: 2434-2441.
6. Hollink IH, Zwaan CM, Zimmermann M, Arentsen-Peters TC, Pieters R, Cloos J et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia 2009; 23: 262-270.
7. Keilholz U, Menssen HD, Gaiger A, Menke A, Oji Y, Oka Y et al. Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia 2005; 19: 1318-1323.
8. Yang L, Han Y, Suarez SF, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007; 21: 868-876.
9. Trka J, Kalinova M, Hrusak O, Zuna J, Krejci O, Madzo J et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: Prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 2002; 16 1381-1389.
10. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F et al Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115-2121.
11. Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: An excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. Br J Haematol 2004; 125: 590-600.
12. Osborne D, Frost L, Tobal K, Yin JAL. Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemia. Bone Marrow Transplant 2005; 36: 67-70.
13. Tamaki H, Ogawa H, Ohyashiki K, Ohyashiki JH, Iwama H, Inoue K et al The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999; 13: 393-399.
14. Bader P, Niemeyer C, Weber G, Coliva T, Rossi V, Kreyenberg H et al WT1 gene expression: Useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia? Eur J Haematol 2004; 73: 25-28.
15. Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 2003; 21: 1988-1995.
16. Hamalainen MM, Kairisto V, Juvonen V, Johansson J, Auren J, Kohonen K et al. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. Eur J Haematol 2008; 80: 201-207.
17. Boublikova L, Kalinova M, Ryan J, Quinn F, O'Marcaigh A, Smith O et al. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: A wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 2006; 20: 254-263.
18. Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, Balgobind BV, Arentsen-Peters ST, Alders M et al. Clinical relevance of Wilms' tumor 1 gene mutations in childhood acute myeloid leukemia. Blood 2009, January (e-pub ahead of print).
19. Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrozek K, Maharry K et al. Wilms Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol 2008; 26: 4595-4602.
20. Nyvold CG, Stentoft J, Braendstrup K, Melsvik D, Moestrup SK, Juhl-Christensen C et al. Wilms' tumor 1 mutation accumulated during therapy in acute myeloid leukemia: Biological and clinical implications. Leukemia 2006; 20: 2051-2054.
21. Summers K, Stevens J, Kakkas I, Smith M, Smith LL, Macdougall F et al Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 2007; 21: 550-551.
22. Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J et al Mutation of the Wilms' Tumor 1 Gene Is a Poor Prognostic Factor Associated With Chemotherapy Resistance in Normal Karyotype Acute Myeloid Leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008; 26: 5429-5435.
23. Gaidzik V, Dohner K. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 2008; 35 346-355.
24. Pollard JA, Zeng R, Ho P, Alonzo T, Gerbing R, Stirewalt D et al. Prevalence and prognostic implications of WT1 mutations in pediatric AML Â: Report from Children's Oncology Group. Blood (ASH annual meeting abstracts) 2008; 112: 58.
25. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
26. Beillard E, Pallisgaard N, van der Velden VHJ, Bi W, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe Against Cancer program. Leukemia 2003; 17 2474-2486.
27. Gabert J, Beillard E, van der Velden V, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
28. van Dongen JJM, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease - Report of the BIOMED-1 Concerted Action: Investigation of Minimal Residual Disease in Acute Leukemia. Leukemia 1999; 13: 1901-1928.
29. Kreuzer KA, Saborowski A, Lupberger J, Appelt C, Na IK, le Coutre P et al. Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: Implications for monitoring human leukaemias. Br J Haematol 2001; 114: 313-318.
30. Pallisgaard N, Hokland P, Bi WL, van der Schoot E, Watzinger F, Lion T et al. Selection of reference genes for the European standardization and quality control program of real-time quantitative RT-PCR analysis of fusion gene transcripts for minimal residual disease follow-up in leukemia patients. Blood 2001; 98: 192B.
31. Beillard E, Pradel V, Aerts J, Barbany G, Bi W, Cave H et al. European standardization and quality control program of real time quantitative RT-PCR analysis of fusion gene transcripts for minimal residual disease detection in leukemia patients. Leukemia 2001; 15: 2006-2007.
32. Gottardi E, Cilloni D, Daly S, Green S, Pallisgaard N, Hokland P et al. Standardization of WT1 mRNA quantification for minimal residual disease (MRD) monitoring in acute leukemia patients: A European LeukemiaNet concerted action. Blood (ASH annual meeting abstracts) 2005; 106: 3295.
33. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: Principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013-1034.
34. The R Foundation for Statistical Computing c/o Institut für Statistik und Wahrscheinlichkeitstheorie der Technischen Universität Wien. R, a language and environment for statistical computing and graphics. University of Vienna, Austria, 2003.
35. Steinbach D, Debatin KM. What do we mean by sensitivity when we talk about detecting minimal residual disease? Leukemia 2008; 22: 1638-1639.